|
Name |
(-)-xylariamide A
|
| Molecular Formula | C14H14ClNO6 | |
| IUPAC Name* |
(2R)-3-(3-chloro-4-hydroxyphenyl)-2-[[(E)-4-methoxy-4-oxobut-2-enoyl]amino]propanoic acid
|
|
| SMILES |
COC(=O)/C=C/C(=O)N[C@H](CC1=CC(=C(C=C1)O)Cl)C(=O)O
|
|
| InChI |
InChI=1S/C14H14ClNO6/c1-22-13(19)5-4-12(18)16-10(14(20)21)7-8-2-3-11(17)9(15)6-8/h2-6,10,17H,7H2,1H3,(H,16,18)(H,20,21)/b5-4+/t10-/m1/s1
|
|
| InChIKey |
KCOKHEIACSQLBQ-ORAHPGNNSA-N
|
|
| Synonyms |
(-)-xylariamide A; cxl017; CHEMBL463133; (?)-Xylariamide A; BDBM50339590; ZINC13347543; (R)-3-(3-chloro-4-hydroxyphenyl)-2-(4-methoxy-4-oxobut-2-enamido)propanoic acid; (2R)-3-(3-chloro-4-hydroxy-phenyl)-2-[[(E)-4-methoxy-4-oxo-but-2-enoyl]amino]propanoic acid; (2R)-3-(3-chloro-4-hydroxyphenyl)-2-[[(E)-4-methoxy-4-oxobut-2-enoyl]amino]propanoic acid
|
|
| CAS | NA | |
| PubChem CID | 11290362 | |
| ChEMBL ID | CHEMBL463133 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 327.71 | ALogp: | 1.5 |
| HBD: | 3 | HBA: | 6 |
| Rotatable Bonds: | 7 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 113.0 | Aromatic Rings: | 1 |
| Heavy Atoms: | 22 | QED Weighted: | 0.536 |
| Caco-2 Permeability: | -5.453 | MDCK Permeability: | 0.00001790 |
| Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.002 |
| Human Intestinal Absorption (HIA): | 0.174 | 20% Bioavailability (F20%): | 0.014 |
| 30% Bioavailability (F30%): | 0.354 |
| Blood-Brain-Barrier Penetration (BBB): | 0.123 | Plasma Protein Binding (PPB): | 73.38% |
| Volume Distribution (VD): | 0.28 | Fu: | 27.99% |
| CYP1A2-inhibitor: | 0.08 | CYP1A2-substrate: | 0.107 |
| CYP2C19-inhibitor: | 0.125 | CYP2C19-substrate: | 0.052 |
| CYP2C9-inhibitor: | 0.111 | CYP2C9-substrate: | 0.496 |
| CYP2D6-inhibitor: | 0.021 | CYP2D6-substrate: | 0.186 |
| CYP3A4-inhibitor: | 0.025 | CYP3A4-substrate: | 0.218 |
| Clearance (CL): | 4.85 | Half-life (T1/2): | 0.943 |
| hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.344 |
| Drug-inuced Liver Injury (DILI): | 0.945 | AMES Toxicity: | 0.013 |
| Rat Oral Acute Toxicity: | 0.029 | Maximum Recommended Daily Dose: | 0.009 |
| Skin Sensitization: | 0.189 | Carcinogencity: | 0.075 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.015 |
| Respiratory Toxicity: | 0.027 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000862 | ![]() |
0.422 | D0U0OT | ![]() |
0.375 | ||
| ENC000325 | ![]() |
0.394 | D08HVR | ![]() |
0.352 | ||
| ENC002317 | ![]() |
0.379 | D0C6OQ | ![]() |
0.299 | ||
| ENC005220 | ![]() |
0.365 | D0P7JZ | ![]() |
0.295 | ||
| ENC000127 | ![]() |
0.352 | D0BA6T | ![]() |
0.289 | ||
| ENC000717 | ![]() |
0.351 | D0V9EN | ![]() |
0.288 | ||
| ENC003452 | ![]() |
0.350 | D03LGG | ![]() |
0.277 | ||
| ENC002095 | ![]() |
0.343 | D0U5CE | ![]() |
0.277 | ||
| ENC001579 | ![]() |
0.340 | D0X5SJ | ![]() |
0.271 | ||
| ENC002436 | ![]() |
0.337 | D01CRB | ![]() |
0.270 | ||